Methotrexate for maintenance of remission in IgG4-related disease

Rheumatology (Oxford). 2015 Oct;54(10):1934-6. doi: 10.1093/rheumatology/kev244. Epub 2015 Jul 2.

Authors

Emanuel Della-Torre¹, Corrado Campochiaro², Enrica Paola Bozzolo³, Lorenzo Dagna², Raffaella Scotti³, Roberto Nicoletti⁴, John H Stone⁵, Maria Grazia Sabbadini²

Affiliations

¹ Università Vita-Salute San Raffaele, Unit of Medicine and Clinical immunology, dellatorre.emanuel@hsr.it.
² Università Vita-Salute San Raffaele, Unit of Medicine and Clinical immunology.
³ Unit of Medicine and Clinical immunology.
⁴ Radiology Department, IRCCS-San Raffaele Scientific Institute, Milan, Italy and.
⁵ Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.

PMID: 26139657
DOI: 10.1093/rheumatology/kev244

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antirheumatic Agents / therapeutic use*
Cost-Benefit Analysis
Female
Follow-Up Studies
Glucocorticoids / therapeutic use
Humans
Immunoglobulin G / blood*
Immunosuppressive Agents / therapeutic use
Male
Methotrexate / therapeutic use*
Middle Aged
Remission Induction / methods
Rheumatic Diseases / drug therapy*
Rheumatic Diseases / immunology*
Treatment Outcome

Substances

Antirheumatic Agents
Glucocorticoids
Immunoglobulin G
Immunosuppressive Agents
Methotrexate